A Phase 1 safety, tolerability, and pharmacokinetic study of single-and multiple-ascending doses of
muvalaplin (LY3473329) 30 mg-800 mg in healthy volunteers
Educational Partners and Supporters
AstraZeneca has provided a sponsorship grant towards this independent programme.
